| Interchangeability, immunogenicity and biosimilars HC Ebbers, SA Crow, AG Vulto, H Schellekens Nature biotechnology 30 (12), 1186-1190, 2012 | 137 | 2012 |
| The safety of switching between therapeutic proteins HC Ebbers, M Muenzberg, H Schellekens Expert opinion on biological therapy 12 (11), 1473-1485, 2012 | 137 | 2012 |
| The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review L Barbier, HC Ebbers, P Declerck, S Simoens, AG Vulto, I Huys Clinical Pharmacology & Therapeutics 108 (4), 734-755, 2020 | 132 | 2020 |
| Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights IC Macdougall, SD Roger, A De Francisco, DJA Goldsmith, H Schellekens, ... Kidney international 81 (8), 727-732, 2012 | 132 | 2012 |
| Use of the conditional marketing authorization pathway for oncology medicines in Europe J Hoekman, WPC Boon, JC Bouvy, HC Ebbers, JP de Jong, ML De Bruin Clinical Pharmacology & Therapeutics 98 (5), 534-541, 2015 | 70 | 2015 |
| Biosimilars: in support of extrapolation of indications HC Ebbers Journal of Crohn's and Colitis 8 (5), 431-435, 2014 | 64 | 2014 |
| Are we ready to close the discussion on the interchangeability of biosimilars? HC Ebbers, H Schellekens Drug Discovery Today 24 (10), 1963-1967, 2019 | 51 | 2019 |
| Interchangeability. An insurmountable fifth hurdle? HC Ebbers, P Chamberlain Generics and Biosimilars Initiative Journal 3 (2), 88-97, 2014 | 40 | 2014 |
| Real-world evidence on etanercept biosimilar SB4 in etanercept-naïve or switching patients: a systematic review HC Ebbers, B Pieper, A Issa, J Addison, U Freudensprung, MF Rezk Rheumatology and Therapy 6, 317-338, 2019 | 39 | 2019 |
| Contribution of animal studies to evaluate the similarity of biosimilars to reference products PJK van Meer, HC Ebbers, M Kooijman, CC Gispen-de Wied, ... Drug discovery today 20 (4), 483-490, 2015 | 30 | 2015 |
| Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab HC Ebbers, PJK van Meer, EHM Moors, AK Mantel-Teeuwisse, ... Drug Discovery Today 18 (17-18), 872-879, 2013 | 30 | 2013 |
| Today’s challenges in pharmacovigilance: what can we learn from epoetins? HC Ebbers, AK Mantel-Teeuwisse, EHM Moors, H Schellekens, ... Drug safety 34, 273-287, 2011 | 29 | 2011 |
| Controversies in establishing biosimilarity: extrapolation of indications and global labeling practices HC Ebbers, P Chamberlain BioDrugs 30, 1-8, 2016 | 28 | 2016 |
| Effective pharmaceutical regulation needs alignment with doctors HC Ebbers, T Pieters, HG Leufkens, H Schellekens Drug discovery today 17 (3-4), 100-103, 2012 | 27 | 2012 |
| Differences between post-authorization adverse drug reactions of biopharmaceuticals and small molecules HC Ebbers, E Al-Temimi, EHM Moors, AK Mantel-Teeuwisse, ... BioDrugs 27, 167-174, 2013 | 25 | 2013 |
| The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals HC Ebbers, AK Mantel-Teeuwisse, FA Sayed-Tabatabaei, EHM Moors, ... European journal of clinical pharmacology 69, 217-226, 2013 | 22 | 2013 |
| The Cost‐Effectiveness of Periodic Safety Update Reports for Biologicals in Europe JC Bouvy, HC Ebbers, H Schellekens, MA Koopmanschap Clinical Pharmacology & Therapeutics 93 (5), 433-442, 2013 | 20 | 2013 |
| A cohort study exploring determinants of safety-related regulatory actions for biopharmaceuticals HC Ebbers, AK Mantel-Teeuwisse, EHM Moors, FAS Tabatabaei, ... Drug safety 35, 417-427, 2012 | 16 | 2012 |
| An introduction to biosimilars for the treatment of retinal diseases: a narrative review SM Hariprasad, RP Gale, CY Weng, HC Ebbers, MF Rezk, R Tadayoni Ophthalmology and Therapy 11 (3), 959-982, 2022 | 15 | 2022 |
| The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product‐specific risks for biologicals: a simulation study NS Vermeer, HC Ebbers, SMJM Straus, HGM Leufkens, TCG Egberts, ... pharmacoepidemiology and drug safety 25 (3), 297-306, 2016 | 13 | 2016 |
